Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST/sclerostin in osteocytes

Life Sciences

Volumn 92, Issue 10, 2013, Pages 533-540

  Kim, Ju Young ^a   Lee, Seong Kyu ^b   Jo, Kyung Jin ^c   Song, Dae Yong ^b   Lim, Dong Mee ^d   Park, Keun Young ^d   Bonewald, Lynda F ^f   Kim, Byung Joon ^d,e  

^a Wonkwang University   (South Korea)

^b Eulji University School of Medicine   (South Korea)

^c Pohang University of Science and Technology (POSTECH)   (South Korea)

^d Konyang University   (South Korea)

^e Gachon University College of Medicine   (South Korea)

^f UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Bone mineral density; Exendin 4; Glucagon like peptide 1 receptor; Osteocytes; Sclerostin

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; MESSENGER RNA; OSTEOCALCIN; SCLEROSTIN;

ANIMAL CELL; ARTICLE; BONE DENSITY; CELL CULTURE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME SYNTHESIS; FEMUR; GLUCOSE TOLERANCE TEST; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOCYTE; OTSUKA LONG EVANS TOKUSHIMA FATTY RAT; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANALYSIS OF VARIANCE; ANIMALS; BLOTTING, WESTERN; BONE DENSITY; BONE MORPHOGENETIC PROTEINS; DIABETES MELLITUS, TYPE 2; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; GENETIC MARKERS; GLUCAGON-LIKE PEPTIDE 1; IMMUNOHISTOCHEMISTRY; MICE; MICE, KNOCKOUT; MICROSCOPY, CONFOCAL; OSTEOCALCIN; OSTEOCYTES; PEPTIDES; RATS; RATS, INBRED OLETF; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, GLUCAGON; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VENOMS;

MUS; RATTUS;

EID: 84875455404     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2013.01.001     Document Type: Article

References (43)

1. L. Achemlal, S. Tellal, F. Rkiouak, A. Nouijai, A. Bezza, and el M. Derouiche Bone metabolism in male patients with type 2 diabetes Clin Rheumatol 24 5 2005 493 496
2. L.F. Bonewald Osteocytes C.J. Rosen, Primer on the metabolic bone diseases and disorders of mineral metabolism 2008 American Society for Bone and Mineral Research Washington, DC 22 27
3. L.F. Bonewald, and M.L. Johnson Osteocytes, mechanosensing and Wnt signaling Bone 42 4 2008 606 615
4. R. Bonfanti, S. Mora, C. Prinster, E. Bognetti, F. Meschi, and M. Puzzovio Bone modeling indexes at onset and during the first year of follow-up in insulin-dependent diabetic children Calcif Tissue Int 60 5 1997 397 400
5. J.A. Clowes, S. Khosla, and R. Eastell Potential role of pancreatic and enteric hormones in regulating bone turnover J Bone Miner Res 20 9 2005 1497 1506
6. I. De Leeuw, and R. Abs Bone mass and bone density in maturity-type diabetics measured by the 125I photon-absorption technique Diabetes 26 12 1977 1130 1135
7. F.J. de Paula, M.C. Horowitz, and C.J. Rosen Novel insights into the relationship between diabetes and osteoporosis Diabetes Metab Res Rev 26 8 2010 622 630
8. H. Dobnig, J.C. Piswanger-Sölkner, M. Roth, B. Obermayer-Pietsch, A. Tiran, and A. Strele Type 2 diabetes mellitus in nursing home patients: effects on bone turnover, bone mass, and fracture risk J Clin Endocrinol Metab 91 9 2006 3355 3363
9. M.E. Doyle, and J.M. Egan Mechanisms of action of glucagon-like peptide 1 in the pancreas Pharmacol Ther 113 3 2007 546 593
10. M. Ellegaard, N.R. Jørgensen, and P. Schwarz Parathyroid hormone and bone healing Calcif Tissue Int 87 1 2010 1 13
11. D.B. Henriksen, P. Alexandersen, N.H. Bjarnason, T. Vilsbøll, B. Hartmann, and E.E. Henriksen Role of gastrointestinal hormones in postprandial reduction of bone resorption J Bone Miner Res 18 12 2003 2180 2189
12. A.M. Inzerillo, and S. Epstein Osteoporosis and diabetes mellitus Rev Endocr Metab Disord 5 3 2004 261 268
13. G.C. Isaia, P. Ardissone, M. Di Stefano, D. Ferrari, V. Martina, and M. Porta Bone metabolism in type 2 diabetes mellitus Acta Diabetol 36 1-2 1999 35 38
14. Y. Kato, J.J. Windle, B.A. Koop, G.R. Mundy, and L.F. Bonewald Establishment of an osteocyte-like cell line, MLO-Y4 J Bone Miner Res 12 12 1997 2014 2023
15. Y. Kitase, L. Barragan, H. Qing, S. Kondoh, J.X. Jiang, and M.L. Johnson Mechanical induction of PGE2 in osteocytes blocks glucocorticoid-induced apoptosis through both the β-catenin and PKA pathways J Bone Miner Res 25 12 2010 2657 2668
16. S.T. Knudsen, C.H. Foss, P.L. Poulsen, N.H. Andersen, C.E. Mogensen, and L.M. Rasmussen Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications Eur J Endocrinol 149 1 2003 39 42
17. M.E. Levin, V.C. Boisseau, and L.V. Avioli Effects of diabetes mellitus on bone mass in juvenile and adult-onset diabetes N Engl J Med 294 5 1976 241 245
18. H.H. Malluche, N. Koszewski, M.C. Monier-Faugere, J.P. Williams, and H. Mawad Influence of the parathyroid glands on bone metabolism Eur J Clin Invest 36 Suppl. 2 2006 23 33
19. L.L. Nielsen, A.A. Young, and D.G. Parkes Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes Regul Pept 117 2 2004 77 88
20. B. Nuche-Berenguer, P. Moreno, P. Esbrit, S. Dapía, J.R. Caeiro, and J. Cancelas Effect of GLP-1 treatment on bone turnover in normal, type 2 diabetic, and insulin-resistant states Calcif Tissue Int 84 6 2009 453 461
21. B. Nuche-Berenguer, P. Moreno, S. Portal-Nuñez, S. Dapía, P. Esbrit, and M.L. Villanueva-Peñacarrillo Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states Regul Pept 159 1-3 2010 61 66
22. B. Nuche-Berenguer, S. Portal-Núñez, P. Moreno, N. González, A. Acitores, and A. López-Herradón Presence of a functional receptor for GLP-1 in osteoblastic cells, independent of the cAMP-linked GLP-1 receptor J Cell Physiol 225 2 2010 585 592
23. B. Nuche-Berenguer, D. Lozano, I. Gutiérrez-Rojas, P. Moreno, M.L. Mariñoso, and P. Esbrit GLP-1 and exendin-4 can reverse hyperlipidic-related osteopenia J Endocrinol 209 2 2011 203 210
24. M.S. Ominsky, C. Li, X. Li, H.L. Tan, E. Lee, and M. Barrero Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones J Bone Miner Res 26 5 2011 1012 1021
25. Y.G. Park, Y.H. Kim, S.K. Kang, and C.H. Kim cAMP-PKA signaling pathway regulates bone resorption mediated by processing of cathepsin K in cultured mouse osteoclasts Int Immunopharmacol 6 6 2006 947 956
26. J.M. Patsch, F.W. Kiefer, P. Varga, P. Pail, M. Rauner, and D. Stupphann Increased bone resorption and impaired bone microarchitecture in short-term and extended high-fat diet-induced obesity Metabolism 60 2 2011 243 249
27. F.J. Paula, and C.J. Rosen Obesity, diabetes mellitus and last but not least, osteoporosis Arq Bras Endocrinol Metabol 54 2 2010 150 157
28. K.E. Poole, R.L. van Bezooijen, N. Loveridge, H. Hamersma, S.E. Papapoulos, and C.W. Löwik Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation FASEB J 19 13 2005 1842 1844
29. M.T. Rosato, S.H. Schneider, and S.A. Shapses Bone turnover and insulin-like growth factor I levels increase after improved glycemic control in noninsulin-dependent diabetes mellitus Calcif Tissue Int 63 2 1998 107 111
30. R. Siddappa, W. Mulder, I. Steeghs, C. van de Klundert, H. Fernandes, and J. Liu cAMP/PKA signaling inhibits osteogenic differentiation and bone formation in rodent models Tissue Eng Part A 15 8 2009 2135 2143
31. M. Sosa, M. Dominguez, M.C. Navarro, M.C. Segarra, D. Hernández, and P. de Pablos Bone mineral metabolism is normal in non-insulin-dependent diabetes mellitus J Diabet Complicat 10 4 1996 201 205
32. R.P. Stolk, P.L. Van Daele, H.A. Pols, H. Burger, A. Hofman, and J.C. Birkenhäger Hyperinsulinemia and bone mineral density in an elderly population: the Rotterdam Study Bone 18 6 1996 545 549
33. K. Tsukiyama, Y. Yamada, C. Yamada, N. Harada, Y. Kawasaki, and M. Ogura Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation after food ingestion Mol Endocrinol 20 7 2006 1644 1651
34. P.L. van Daele, R.P. Stolk, H. Burger, D. Algra, D.E. Grobbee, and A. Hofman Bone density in non-insulin-dependent diabetes mellitus. The Rotterdam Study Ann Intern Med 122 6 1995 409 414
35. T. Vilsbøll, T. Krarup, C.F. Deacon, S. Madsbad, and J.J. Holst Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients Diabetes 50 3 2001 609 613
36. M. Wakasugi, R. Wakao, M. Tawata, N. Gan, K. Koizumi, and T. Onaya Bone mineral density measured by dual energy X-ray absorptiometry in patients with non-insulin-dependent diabetes mellitus Bone 14 1 1993 29 33
37. J.S. Walsh, and D.B. Henriksen Feeding and bone Arch Biochem Biophys 503 1 2010 11 19
38. D.G. Winkler, M.K. Sutherland, J.C. Geoghegan, C. Yu, T. Hayes, and J.E. Skonier Osteocyte control of bone formation via sclerostin, a novel BMP antagonist EMBO J 22 23 2003 6267 6276
39. X. Xia, R. Kar, J. Gluhak-Heinrich, W. Yao, N.E. Lane, and L.F. Bonewald Glucocorticoid-induced autophagy in osteocytes J Bone Miner Res 25 11 2010 2479 2488
40. D. Xie, H. Cheng, M. Hamrick, Q. Zhong, K.H. Ding, and D. Correa Glucose-dependent insulinotropic polypeptide receptor knockout mice have altered bone turnover Bone 37 6 2005 759 769
41. D. Xie, Q. Zhong, K.H. Ding, H. Cheng, S. Williams, and D. Correa Glucose-dependent insulinotropic peptide-overexpressing transgenic mice have increased bone mass Bone 40 5 2007 1352 1360
42. C. Yamada, Y. Yamada, K. Tsukiyama, K. Yamada, N. Udagawa, and N. Takahashi The murine glucagon-like peptide-1 receptor is essential for control of bone resorption Endocrinology 149 2 2008 574 579
43. S. Zhao, Y.K. Zhang, S. Harris, S.S. Ahuja, and L.F. Bonewald MLO-Y4 osteocyte-like cells support osteoclast formation and activation J Bone Miner Res 17 11 2002 2068 2079